+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2015-08-05Number of Pages: 101

Dyslipidemia Drugs Market: (By Drug Class - Statins, Bile Acid Resins, Fibric Acid and Omega-3 Fatty Acid Derivatives, Niacins, Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023


Dyslipidemia is a chronic metabolic syndrome, characterized by improper level of low density lipoprotein, high density lipoprotein, and triglycerides. This study on the dyslipidemia drugs market involves the analysis of a wide range of therapeutics that help patients to treat lipid disorders. The dyslipidemia drugs market promises lucrative growth opportunities for pharmaceutical manufacturers due to increasing demand and prescriptions of these medications. According to the Centers for Disease Control and Prevention, cholesterol abnormalities are rapidly increasing in developed regions such as North America and Europe. Moreover, several articles published in open journals stated that demand for lipid lowering drugs is increasing in countries such as China, India, and Japan. However, loss of patent exclusivity of molecules such as Crestor, Zetia, and Vytorin is expected to hamper the growth of the market during the forecast period.

This report comprises a detailed study of various drug classes for the treatment of dyslipidemia. The dyslipidemia drugs market has been segmented into statins, bile acid resins, fibric acid derivatives, niacins, and others (combination drugs and cholesterol absorption inhibitors). The statins segment comprises combined market revenue of statin drugs such as atorvastatin, fluvastatin, rosuvastatin, pravastatin, simvastatin, pitavastatin, and lovastatin. The bile acid resins segment included resins such as Cholestyramine, Colestipol, Colesevelam, and Cholybar. The fibric acid, and omega-3 fatty acid derivatives segment comprises generic drugs such as Fenofibrate, Clofibrate, and Bezafibrate. Other branded omega-3 fatty acids include Lovaza, Vascespa, and Omtryg. Niacins includes drugs such as Niaspan, Slo-Niacin, and Niacor. The others segment encompasses market analysis of combination drug therapies such as Advicor, Vytorin, and Caduet, as well as cholesterol inhibitor drugs. The market size and forecast for each drug class has been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (% CAGR) for the forecast period from 2015 to 2023 for each drug class, considering 2013 to 2014 as the historical and base year, respectively.

By geography, the dyslipidemia drugs market has been studied for five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Each region has been further divided into major countries i.e., North America: the U.S. and Canada; Europe: Germany, France, the U.K. and Rest of Europe; Asia Pacific: China, Japan, India and Rest of APAC; Latin America: Brazil and Rest of LATAM; Middle East and Africa: South Africa and Rest of MEA. The market size and forecast for each region and country has been estimated for the period 2013 to 2023 in terms of revenue (USD million). The report also provides the compound annual growth rate (CAGR %) during the forecast period from 2015 to 2023 for all the regions and countries mentioned above.

The market overview section of the report discusses the market dynamics with respect to the market drivers, restraints, and opportunities. This section also covers information on epidemiology, etiology, dyslipidemia diagnostics, trends and future aspects, and market attractiveness analysis, by geography of the dyslipidemia drugs market. A list of recommendations for existing and new players to enter the market and enhance their position is also provided in the report. The report concludes with company profiles of key players operating in various drug classes of the market. Each company profile includes business overview, financial overview, product portfolio, business strategies, and recent developments of the respective market player. Prominent players in the dyslipidemia drugs market that have been profiled in the report include Abbott Laboratories, Amgen, Inc., Pfizer, Inc., Novartis AG, Mylan N.V., Merck & Co., Inc., and AstraZeneca plc

The global dyslipidemia drugs market is segmented as follows:
  • Global Dyslipidemia Drugs Market, by Drug Class
    • Statins
    • Bile Acid Resins
    • Fibric Acid and Omega-3 Fatty Acid Derivatives
    • Niacins
    • Others (Combination Drugs and Cholesterol Absorption Inhibitors)
  • Global Dyslipidemia Drugs Market, by Geography
    • North America
    • Europe
    • Asia-Pacific
    • Latin America
    • Middle East and Africa (MEA)


Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
      1.3.1 Sources
               1.3.1.1 Secondary Research
               1.3.1.2 Primary Research
               1.3.1.3 Assumption
1.4 List of Abbreviations

Chapter 2 Executive Summary
2.1 Market Snapshot: Dyslipidemia Drugs Market (2014 & 2023)
2.2 Dyslipidemia Drugs Market, by Drug Class, 2014 (USD Million)
      2.2.1 Comparative Analysis: Dyslipidemia Drugs Market, by Geography, 2014 and 2023 (Value %)

Chapter 3 Market Overview
3.1 Overview
3.2 Epidemiology: Dyslipidemia
3.3 Etiology of Dyslipidemia
      3.3.1 Primary Causes (genetic causes of dyslipidemia)
      3.3.2 Secondary Causes (lifestyle factors)
3.4 Dyslipidemia Diagnostics
      3.4.1 Serum Lipid Profile Measurement (total cholesterol, HDL, LDL, VLDL, etc.)
      3.4.2 Other Tests (lipoprotein-A tests, apo lipoprotein B tests, etc.)
      3.4.3 Secondary Causes Screening and Diagnostics
3.5 Trends and Future Aspects in Dyslipidemia Therapeutics (e.g. PCSK9, CETP inhibitors, etc.)
3.6 Market Dynamics
      3.6.1 Market Drivers
               3.6.1.1 Global increasing prevalence of population with cholesterol and triglyceride abnormalities expected to propel the market
               3.6.1.2 Rise in obese and diabetic populations is expected to increase the incidence of dyslipidemia, and thus demand for dyslipidemia drugs
               3.6.1.3 Extensive research and development changes bring turnaround changes in the dyslipidemia drugs market
               3.6.1.4 Rising disease awareness through promotional activities
      3.6.2 Market Restraints
               3.6.2.1 Impending patent expirations to deplete profit margins
               3.6.2.2 Discontinuation of novel dyslipidemia drugs
      3.6.3 Opportunities
               3.6.3.1 Expanding footprint in emerging nations to generate high sales growth
               3.6.3.2 Biological therapies for the treatment of dyslipidemia
               3.6.3.3 Development of molecules from newer class of dyslipidemia drugs provide a ladder for growth
               3.6.3.4 Strategic collaborations for new drug development
3.7 Market Attractiveness Analysis: Dyslipidemia Drugs Market, by Geography
3.8 Market Share by Key Players of Global Dyslipidemia Drugs Market, 2014 (Value %)
      3.8.1 Global Dyslipidemia Drugs Market Share Analysis, by Key Players, 2014 (%)

Chapter 4 Dyslipidemia Drugs Market, by Drug Class
4.1 Introduction
      4.1.1 Dyslipidemia Drugs Market Revenue, by Drug Class, 2013 – 2023 (USD Million)
4.2 Statins
      4.2.1 Statins Market Revenue, 2013 – 2023 (USD Million)
4.3 Bile Acid Resins (Cholestyramine, Colestipol, Colesevelam, etc.)
      4.3.1 Bile Acid Resins Market Revenue, 2013 – 2023 (USD Million)
4.4 Fibric Acid and Omega-3 Fatty Acid Derivatives (Fenofibrate, Gemfibrozil, Vascespa, etc.)
     4.4.1 Fibric Acid and Omega-3 Fatty Acid Derivatives Market Revenue, 2013 – 2023 (USD Million)
4.5 Niacins (Niacor, Niaspan, Slo-Niacin, etc.)
      4.5.1 Niacins Market Revenue, 2013 – 2023 (USD Million)
4.6 Others (Combination drugs such as lovastatin and niacin, atorvastatin and amlodipine, simvastatin and ezetimibe, cholesterol absorption inhibitors, etc.)
      4.6.1 Others Market Revenue, 2013 – 2023 (USD Million)
4.7 Pipeline Drugs
     4.7.1 Dyslipidemia Drugs Market Revenue with Pipeline Drugs, by Drug Class, 2013 – 2023 (USD Million)
      4.7.2 Anacetrapib (MK-0859)
              4.7.2.1 Anacetrapib Market Revenue, 2018 – 2023 (USD Million)
      4.7.3 Evacetrapib (LY2484595)
              4.7.3.1 Evacetrapib Market Revenue, 2017 – 2023 (USD Million)
      4.7.4 Praluent (Alirocumab)
              4.7.4.1 Praluent Market Revenue, 2015 – 2023 (USD Million)
      4.7.5 Evolocumab (Repatha)
              4.7.5.1 Evolocumab Market Revenue, 2015 – 2023 (USD Million)
      4.7.6 Bococizumab (RN316)
              4.7.6.1 Bococizumab Market Revenue, 2019 – 2023 (USD Million)

Chapter 5 Dyslipidemia Drugs Market, by Geography
5.1 Overview
      5.1.1 Dyslipidemia Drugs Market Revenue, by Geography, 2013 – 2023 (USD Million)
5.2 North America
      5.2.1 North America Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million)
5.3 Europe
      5.3.1 Europe Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million)
5.4 Asia Pacific
      5.4.1 Asia Pacific Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million)
5.5 Latin America
      5.5.1 Latin America Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million)
5.6 Middle East and Africa
      5.6.1 Middle East and Africa Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million)

Chapter 6 Recommendations
6.1 Developing combination drugs for the treatment of dyslipidemia
6.2 Major research-based drug developing companies must collaborate with hospitals or acquire pharma establishments to develop more effective dyslipidemia treatments
6.3 Global players should target low to medium income countries to generate higher revenues

Chapter 7 Company Profiles
7.1 Abbott Laboratories
      7.1.1 Company Overview
      7.1.2 Financial Overview
      7.1.3 Product Portfolio
      7.1.4 Business Strategies
      7.1.5 Recent Developments
7.2 AstraZeneca plc
      7.2.1 Company Overview
      7.2.2 Financial Overview
      7.2.3 Product Portfolio
      7.2.4 Business Strategies
      7.2.5 Recent Developments
7.3 Amgen, Inc.
      7.3.1 Company Overview
      7.3.2 Financial Overview
      7.3.3 Product Portfolio
      7.3.4 Business Strategies
      7.3.5 Recent Developments
7.4 Bayer AG
      7.4.1 Company Overview
      7.4.2 Financial Overview
      7.4.3 Product Portfolio
      7.4.4 Business Strategies
      7.4.5 Recent Developments
7.5 Bristol-Myers Squibb Company
      7.5.1 Company Overview
      7.5.2 Financial Overview
      7.5.3 Product Portfolio
      7.5.4 Business Strategies
      7.5.5 Recent Developments
7.6 Mylan N.V.
      7.6.1 Company Overview
      7.6.2 Financial Overview
      7.6.3 Product Portfolio
      7.6.4 Business Strategies
      7.6.5 Recent Developments
7.7 Novartis AG
      7.7.1 Company Overview
      7.7.2 Financial Overview
      7.7.3 Product Portfolio
      7.7.4 Business Strategies
      7.7.5 Recent Developments
7.8 Merck & Co., Inc.
      7.8.1 Company Overview
      7.8.2 Financial Overview
      7.8.3 Product Portfolio
      7.8.4 Business Strategies
      7.8.5 Recent Developments
7.9 Pfizer, Inc.
      7.9.1 Company Overview
      7.9.2 Financial Overview
      7.9.3 Product Portfolio
      7.9.4 Business Strategies
      7.9.5 Recent Developments
7.10 Shionogi & Co., Ltd.
      7.10.1 Company Overview
      7.10.2 Financial Overview
      7.10.3 Product Portfolio
      7.10.4 Business Strategies
      7.10.5 Recent Developments
7.11 Takeda Pharmaceutical Company Limited
      7.11.1 Company Overview
      7.11.2 Financial Overview
      7.11.3 Product Portfolio
      7.11.4 Business Strategies
      7.11.5 Recent Developments
7.12 Teva Pharmaceutical Industries Ltd.
      7.12.1 Company Overview
      7.12.2 Financial Overview
      7.12.3 Product Portfolio
      7.12.4 Business Strategies
      7.12.5 Recent Developments

List of Figures

FIG. 1 Dyslipidemia Drugs Market: Market Segmentation
FIG. 2 Dyslipidemia Drugs Market, by Drug Class, 2014 (USD Million)
FIG. 3 Comparative Analysis: Dyslipidemia Drugs Market, by Geography, 2014 and 2023 (Value %)
FIG. 4 Market Attractiveness Analysis: Dyslipidemia Drugs Market, by Geography
FIG. 5 Global Dyslipidemia Drugs Market: Market Share, by Key Players, 2014 (%)
FIG. 6 Statins Market Revenue, 2013 – 2023 (USD Million)
FIG. 7 Bile Acid Resins Market Revenue, 2013 – 2023 (USD Million)
FIG. 8 Fibric Acid and Omega-3 Fatty Acid Derivatives Market Revenue, 2013 – 2023 (USD Million)
FIG. 9 Niacins Market Revenue, 2013 – 2023 (USD Million)
FIG. 10 Others Market Revenue, 2013 – 2023 (USD Million)
FIG. 11 Anacetrapib Market Revenue, 2018 – 2023 (USD Million)
FIG. 12 Evacetrapib Market Revenue, 2017 – 2023 (USD Million)
FIG. 13 Praluent Market Revenue, 2015 – 2023 (USD Million)
FIG. 14 Evolocumab Market Revenue, 2015 – 2023 (USD Million)
FIG. 15 Bococizumab Market Revenue, 2019 – 2023 (USD Million)
FIG. 16 Abbott Laboratories: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 17 AstraZeneca plc: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 18 Amgen, Inc.: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 19 Bayer AG: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 20 Bristol-Myers Squibb Company: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 21 Mylan N.V.: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 22 Novartis AG: Annual Revenues, 2012 – 2014 (USD Million)
FIG. 23 Merck & Co., Inc.: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 24 Pfizer, Inc.: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 25 Shionogi & Co., Ltd.: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 26 Takeda Pharmaceutical Company Limited: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 27 Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2012 – 2014 (USD Million)

List of Tables

TABLE 1 List of Abbreviations
TABLE 2 Market Snapshot: Dyslipidemia Drugs Market (2014 & 2023)
TABLE 3 Number of People with Diabetes (20 Years – 79 years), by Country/Territory, 2013 (Millions)
TABLE 4 Impact Analysis of Market Drivers
TABLE 5 Impact Analysis of Market Restraints
TABLE 6 Dyslipidemia Drugs Market Revenue, by Drug Class, 2013 – 2023 (USD Million)
TABLE 7 Dyslipidemia Drugs Market Revenue with Pipeline Drugs, by Drug Class, 2013 – 2023 (USD Million)
TABLE 8 Dyslipidemia Drugs Market Revenue, by Geography, 2013 – 2023 (USD Million)
TABLE 9 North America Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million)
TABLE 10 Europe Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million)
TABLE 11 Asia Pacific Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million)
TABLE 12 Latin America Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million)
TABLE 13 Middle East and Africa Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million)


Dyslipidemia is a chronic metabolic disease, characterized by abnormal amount of low density lipoprotein, high density lipoprotein and triglyceride levels. Abnormal lipid level is also one of the major risk factor for the cardiovascular diseases such as atherosclerosis, hypertension and others. The range of therapeutics which includes statins, bile acid resins, cholesterol absorption inhibitors, fibric acid derivatives, omega-3 fatty acid derivatives and niacins are used for the treatment and mitigation of dyslipidemia disorder. Additionally, combination therapies such as statin and fibric acid analogs, ezetimibe and statins (Vytorin), niacins and statins (Advicor) and others are also used for effective treatment of dyslipidemia. Increasing incidences of dyslipidemia in developed (i.e. North America and Europe) and developing (i.e. Asia Pacific and Latin America) regions coupled with rising number of prescription for drugs such as statins and fibric acid derivatives drives the dyslipidemia drugs market growth. However, increase in the number of year on year patent expirations of blockbuster drugs such as Lipitor, Vytorin, Zetia and Crestor is expected to hamper the growth of dyslipidemia drugs market. This market was valued at USD 17,858.3 million in 2014 and is projected to contract at a CAGR of -10.3% from 2015 to 2023 to reach USD 6,888.9 million by 2023.

The global dyslipidemia drugs market is categorized into different drug classes such as statins, bile acid resins, fibric acid and omega-3 fatty acid derivatives, niacins and others (cholesterol absorption inhibitors and combination drugs). Statins accounted for the largest market, captured almost 59.3% share of total dyslipidemia drugs market in 2014. High efficacy of statin drugs coupled with increasing acceptance of blockbuster statin drugs such as Lipitor and Crestor helped statin drugs to record highest share in 2014. However, niacins market is expected to grow with lowest CAGR as compared to other dyslipidemia drugs owing to decrease in sale of Abbott Laboratories’ brand drug Niaspan which will negatively affect the overall growth of the market.
 
Global dyslipidemia drugs market, by geography is segmented as North America, Europe, Asia Pacific, Latin America and Middle East and Africa. In 2014, North America dominated the global dyslipidemia drugs market. Positive government approval policies coupled with consistent rise in the incidence of dyslipidemia in the region stimulates the growth of dyslipidemia drugs market in North America. Europe accounted for the second largest share i.e. around 25% of the total market in 2014 owing to the favorable growth conditions for pharmaceutical manufacturers due to affordability for branded formulations by consumers. Germany recorded the largest market in 2014 and is expected to dominate the European dyslipidemia drugs market during the study period. High prevalence rate coupled with rising demand for dyslipidemia drug therapy in Germany boosted the growth of the market.
 
Some of the prominent players in the global dyslipidemia drugs market are Pfizer, Inc., GlaxoSmithKline, Novartis AG, AstraZeneca plc, Daiichi Sankyo Company Limited, Merck & Co., Inc., Amgen, Inc., Abbott Laboratories, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, Bayer Healthcare and others.

dyslipidemia-market


A complete brochure for this research is available for download.

Interact with our pool of experienced analysts for any report related queries